AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33927121
Drug: (tissue inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (tissue inhibitor of metalloproteinases‐2)•(insulin‐like growth factor‐binding protein 7) patterns
Trial: 35276894
Drug: Higher Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Protein (HP) diet (1.2 g/kg BW)
Trial: 35276894
Drug: Normal Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Protein (NP) diet (0.8 g/kg BW)
Trial: 32624444
Drug: Carbohydrate antigen
RxNorm normalized name: Carbohydrate antigen 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate antigen 125-guided diuretic strategy
Trial: 32674229
Drug: Carbohydrate‐whey protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐whey protein solution (CHP)
Trial: 33586360
Drug: Anlotinib 12
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg on days 1–14 (repeated every 21 days)
Trial: 33875429
Drug: Tebipenem pivoxil
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 600 mg
Trial: 33875429
Drug: Tebipenem pivoxil
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 1200 mg
Trial: 33409459
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day
Trial: 34676521
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SFI) combined with standardized post-resuscitation care bundle (PRCB)
Trial: 32933452
Drug: Pain Neuroscience
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Neuroscience Education (PNE) sessions (six 15-minute sessions) along with physical therapy
Trial: 32933452
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy with PNE
Trial: 33541288
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care of treatment & SBRT to all bone metastases
Trial: 34327227
Drug: Pulsed Electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Electromagnetic Field Treatment (PEMF)
Trial: 33791385
Drug: Periocular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injection of triamcinolone acetonide (TA) administered once every 3 weeks for a total of 3 times.
Trial: 33791385
Drug: Subpalpebral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subpalpebral injection of botulinum toxin type A (BTXA) given as a single administration.
Trial: 33994585
Drug: C-Reactive Protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-Reactive Protein (CRP) and Sequential Organ Failure Assessment (SOFA) score at admission
Trial: 36239414
Drug: Psychoanalytic Treatment
RxNorm normalized name: PSYCHOANALEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic Treatment (PAT)
Trial: 34498484
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) for VTE prevention
Trial: 35978355
Drug: Integrated smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated smoking cessation therapy consisting of weekly brief behavioural interventions and prescription-free nicotine replacement products (nicotine lozenges, patches, and chewing gum) for 16 weeks (with an option to extend by 8 weeks).
Trial: 33518321
Drug: Glycyrrhiza polysaccharide
RxNorm normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhiza polysaccharide (GCP) 200 mg/kg
Trial: 33518321
Drug: Glycyrrhiza polysaccharide
RxNorm normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhiza polysaccharide (GCP) 500 mg/kg
Trial: 33518321
Drug: Glycyrrhiza polysaccharide
RxNorm normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhiza polysaccharide (GCP) 1,000 mg/kg
Trial: 33518321
Drug: Glycyrrhiza polysaccharide
RxNorm normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhiza polysaccharide (GCP) 1,500 mg/kg
Trial: 38319865
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg
Trial: 33724473
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with simultaneous bone augmentation
Trial: 36410472
Drug: efdamrofusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efdamrofusp alfa 2 mg
Trial: 36410472
Drug: efdamrofusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efdamrofusp alfa 4 mg
Trial: 34301613
Drug: aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aflibercept 2 mg
Trial: 36410472
Drug: efdamrofusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efdamrofusp alfa 2 mg and 4 mg
Trial: 32498248
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day ubiquinol (Ubq150)
Trial: 36472134
Drug: lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemborexant 10 mg
Trial: 33576735
Drug: lemborexant 5
RxNorm normalized name: lemborexant 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemborexant 5 mg and 10 mg
Trial: 35046055
Drug: IP cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker), and IP IFNa at 2, 6, and 18 million units (MU) in cohorts 2, 3, and 4 respectively
Trial: 35046055
Drug: IP cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker)
Trial: 33020646
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of dabrafenib and trametinib
Trial: 33020646
Drug: Continuous dosing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dosing of dabrafenib and trametinib
Trial: 33513714
Drug: Marine protein
RxNorm normalized name: Ascorbic Acid/Biotin/Coenzyme Q10/Grape Seed Extract/Hydrated Silica/Marine Protein/Mucopolysaccharides/Selenium/Vitamin A/Vitamin D/Vitamin E/Zinc 62 MG-50 MCG-5 MG-15 MG-60 MG-83 MCG-2417 IU-51 IU-25.5 IU-1.8 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine protein hydrolysate (MPH) 3 g
Trial: 32675537
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (2 postoperative doses)
Trial: 32675537
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 postoperative doses)
Trial: 32488856
Drug: Coriandrum sativum
RxNorm normalized name: CORIANDRUM SATIVUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coriandrum sativum extract (300 mg/kg/day)
Trial: 32030921
Drug: 7-day proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day proton pump inhibitor (PPI)-based standard triple therapy (STT; PPI-clarithromycin-amoxicillin)
Trial: 32030921
Drug: 14-day proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day proton pump inhibitor (PPI)-based standard triple therapy (STT; PPI-clarithromycin-amoxicillin)
Trial: 35850884
Drug: Eyebrow suspension
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eyebrow suspension with nylon thread (ESN)
Trial: 32417468
Drug: Other healthcare-related
RxNorm normalized name: OTHER DRUGS FOR ACID RELATED DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other healthcare-related resources (e.g., CDC, WebMD)
Trial: 32074281
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal pessaries 400 mg bid
Trial: 32074281
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal gel 90 mg od
Trial: 32396179
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with open reduction and internal plate fixation (n=38)
Trial: 36104702
Drug: Vaporized nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaporized nicotine products (VNPs) - pod (40 mg/mL nicotine salt) and tank device (18 mg/mL freebase nicotine)
Trial: 36104702
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT) - gum or lozenge (4 mg)
Trial: 33224416
Drug: Ibuprofen (10mg/kg)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (10mg/kg)
Trial: 33224416
Drug: Paracetamol (15mg/kg)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (15mg/kg)
Trial: 36939774
Drug: Ibuprofen treatment
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen treatment
Trial: 35988360
Drug: CIPRO+FLUO (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIPRO+FLUO (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 % otic solution)
Trial: 35988360
Drug: CIPRO (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIPRO (ciprofloxacin 0.3 % otic solution)
Trial: 35988360
Drug: FLUO (fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLUO (fluocinolone acetonide 0.025 % otic solution)
Trial: 34939004
Drug: Exercise is
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise is Medicine (EIM) intervention framework (mHealth components plus twice‐weekly small‐group directed exercise sessions)
Trial: 37640035
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg twice daily
Trial: 33752164
Drug: sprifermin 100
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprifermin 100 µg every 6 months (q6mo)
Trial: 34913147
Drug: Simple Combination
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Combination Therapy (SCT)
Trial: 32514040
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of oxytocin (OT) in the minimal social contact (MSC) condition
Trial: 32514040
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of oxytocin (OT) in the no-social-contact (NoC) condition
Trial: 35019769
Drug: Biotène dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotène dry mouth oral rinse
Trial: 32820573
Drug: Epidemiological agent-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidemiological agent-based models (ABMs) such as AceMod for the COVID-19 epidemic in Australia
Trial: 32820573
Drug: Epidemiological agent-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidemiological agent-based models (ABMs)
Trial: 37222252
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg/d)
Trial: 34265462
Drug: mRNA BNT162b2
RxNorm normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA BNT162b2 (2 doses)
Trial: 34265462
Drug: mRNA-1273 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (1 dose)
Trial: 34265462
Drug: mRNA-1273 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (2 doses)
Trial: 33338947
Drug: Simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin plus metformin
Trial: 35987487
Drug: Trauma-Focused Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Therapy (TFT) - Prolonged Exposure or Cognitive Processing Therapy
Trial: 35987487
Drug: Non-Trauma-Focused Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Trauma-Focused Therapy (NTFT) - Present Centered Therapy (PCT)
Trial: 34477993
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy
Trial: 35320927
Drug: ADD (pecans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADD (pecans 68 g/d)
Trial: 35320927
Drug: SUB (pecans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUB (pecans 68 g/d with isocaloric substitution)
Trial: 33527654
Drug: Ambulatory medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory medication intervention (diuretic up-titration PRN)
Trial: 34085466
Drug: Joint administration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint administration of acupuncture, western and herbal medicines, and bamboo-jar-cupping (kept for 10 min), treatment conducted once a day for 2 weeks.
Trial: 34085466
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (acupuncture + cupping) vs Control group (acupuncture + conventional western and herbal medicines).
Trial: 616505834
Drug: Fibre-enriched nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre-enriched nutrition solution
Trial: 33054003
Drug: Improved methods
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved methods of physical training with interval cyclic training on treadmills and sensory tracks, therapeutic exercises in the gym (daily, 5 times a week, for a course of 10 procedures)
Trial: 33054003
Drug: Enhanced external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced external counterpulsation, general dry air carbon dioxide, infrared matrix laser therapy
Trial: 32447296
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg IV every 4 weeks for 24 cycles) + concurrent chemoradiotherapy
Trial: 32447296
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + concurrent chemoradiotherapy
Trial: 35177777
Drug: Oral hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydroxyurea 10-20 mg/kg/day
Trial: 32108254
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group (no implant material injection)
Trial: 36201851
Drug: ShipShape enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ShipShape enhanced with acceptance and commitment therapy
Trial: 35841586
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of danofloxacin at 10 mg/kg
Trial: 35841586
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of danofloxacin at 10 mg/kg
Trial: 35841586
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of danofloxacin at 10 mg/kg
Trial: 32752228
Drug: Brief group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief group cognitive behavioral therapy (BG-CBT) - six brief weekly sessions
Trial: 33220462
Drug: Bencycloquidium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencycloquidium bromide (BCQB) 125 μg
Trial: 33220462
Drug: Bencycloquidium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencycloquidium bromide (BCQB) 250 μg
Trial: 33220462
Drug: Bencycloquidium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencycloquidium bromide (BCQB) 1125 μg
Trial: 35501736
Drug: 6-thioguanine (6TG)
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-thioguanine (6TG) at a low dose of 2.5–12.5 mg/m2/day, combined with reduced 6-mercaptopurine (6MP) starting dose of 50 mg/m2/day
Trial: 35501736
Drug: Methotrexate (MTX)/6-mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX)/6-mercaptopurine (6MP) maintenance therapy
Trial: 32776907
Drug: Kuntai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai capsule
Trial: 32067512
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg deferasirox
Trial: 32067512
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole and 30 mg/kg deferasirox
Trial: 32067512
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg vitamin E and 30 mg/kg deferasirox
Trial: 32067512
Drug: 420 mg
RxNorm normalized name: choline 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg silymarin and 30 mg/kg deferasirox
Trial: 35821886
Drug: Diagnostic performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic performance of ADC value to differentiate CC and normal cervix
Trial: 32901379
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using diode laser (980 nm, 0.3 W) for 10 seconds at six spots along the midpalatal suture during active and passive phases of rapid palatal expansion.
Trial: 39501183
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin daily
Trial: 35215405
Drug: NMN (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMN (250 mg) administered once a day for 12 weeks
Trial: 34470137
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200 mg daily)
Trial: 34470137
Drug: 17-alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-alpha-hydroxyprogesterone caproate (17OHP-C) (250 mg intramuscular weekly)
Trial: 33741236
Drug: Weekly voice
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly voice therapy
Trial: 32016386
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous zoledronate (ZZ, n = 16)
Trial: 37852737
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone
Trial: 37976067
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d)
Trial: 35372875
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil and/or aspirin
Trial: 33408073
Drug: Circulating 27‐OHC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating 27‐OHC at or above the fourth quartile (?201 ng/mL)
Trial: 33408073
Drug: Circulating 27‐OHC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating 27‐OHC below the first quartile (<138 ng/mL)
Trial: 34089503
Drug: ctDNA-guided adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA-guided adjuvant chemotherapy (AC)
Trial: 33563173
Drug: Gabapentin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (800 mg/day)
Trial: 38770804
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy
Trial: 35409640
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence
Trial: 35405631
Drug: Laser auriculotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser auriculotherapy (10 sessions, twice a week)
Trial: 34825617
Drug: Titrated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated group (received propofol at a rate of 1 mg/kg/min until the Observer's Assessment of Alertness/Sedation scale score reached 1 point)
Trial: 34825617
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (received 2 mg/kg propofol at a rate of 250 mg/min)
Trial: 35562711
Drug: Memantine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (5 mg/day initially, increased to 20 mg/day over 4 weeks)
Trial: 36153153
Drug: AVP booster
RxNorm normalized name: AVP-21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP booster dose in Group A (on schedule)